Institute of BioPharmaceutical Research, Liaocheng University, 1 Hunan Road, Liaocheng 252000, PR China.
J Med Chem. 2023 Oct 12;66(19):13838-13857. doi: 10.1021/acs.jmedchem.3c01372. Epub 2023 Sep 26.
In this study, PD-L1 and CYP51 were selected as key dual-target enzymes, which play an important role in the process of fungal proliferation and immune suppression. A series of novel bifonazole dual-target compounds were designed through the method of fragment combination. Their chemical structure was synthesized, characterized, and evaluated. Among them, the compounds () exhibited excellent antifungal and antidrug-resistant fungal activity in vitro. In particular, the preferred compound with high-efficiency dual-target inhibitor ability could block the fungal proliferation and activate the organism's immune efficacy. Moreover, the corresponding covalent organic framework carrier was also successfully constructed to improve its bioavailability. This significantly accelerated the body's recovery process from fungal infection in . In summary, this study expanded the scientific frontier of antifungal drugs and provided a feasible candidate pathway for clinical treatment of fungal infections.
在这项研究中,选择 PD-L1 和 CYP51 作为关键的双重靶标酶,它们在真菌增殖和免疫抑制过程中发挥重要作用。通过片段组合的方法设计了一系列新型的比伏康唑双重靶标化合物。对它们的化学结构进行了合成、表征和评估。其中,化合物()在体外表现出优异的抗真菌和抗耐药真菌活性。特别是具有高效双重靶标抑制能力的优选化合物能够阻断真菌的增殖并激活机体的免疫功效。此外,还成功构建了相应的共价有机骨架载体以提高其生物利用度。这显著加速了在体内从真菌感染中恢复的过程。总之,本研究拓展了抗真菌药物的科学前沿,为临床治疗真菌感染提供了可行的候选途径。